← Back to Search

Annuloplasty Ring

Percutaneous Ring Annuloplasty for Tricuspid Regurgitation

N/A
Recruiting
Research Sponsored by Cardiac Implants LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
New York Heart Associate Classification ≥ II.
Moderate to severe functional tricuspid regurgitation (TR) defined by ASE guidelines and the European Association of Echocardiography guidelines.
Must not have
Aortic, mitral and/or pulmonic valve stenosis and/or regurgitation more than moderate.
Cerebro-Vascular Accident within the previous 3 months.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year post-adjustment
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a device called the CI annuloplasty ring, which helps a faulty heart valve close properly. It targets patients with moderate or worse tricuspid regurgitation. The ring is inserted through a vein in the neck and can be adjusted later to ensure it fits well and reduces the valve opening size.

Who is the study for?
Adults over 18 with moderate to severe functional tricuspid regurgitation, a heart condition where the valve doesn't close tightly. They must have a left ventricular ejection fraction of at least 30%, suitable anatomy for the device, and be able to follow study procedures. Excluded are those with recent heart failure hospitalization, severe right ventricle issues, high lung artery pressure, or other conditions that could interfere with the trial.
What is being tested?
The trial is testing a new Cardiac Implants Percutaneous Ring Annuloplasty System designed for people suffering from significant tricuspid valve leakage. It involves placing an annuloplasty ring via catheter and adjusting it after about three months to see if it improves heart function.
What are the potential side effects?
Potential side effects may include complications related to catheter insertion such as bleeding or infection, adverse reactions to materials in the device like stainless steel or nitinol, and possible interference with existing pacemaker or defibrillator leads.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My heart condition limits my physical activity.
Select...
My heart valve issue is moderate to severe, as per specific guidelines.
Select...
I am 18 years old or older.
Select...
I still have symptoms of heart failure despite taking all my medications.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have moderate to severe heart valve issues.
Select...
I have not had a stroke in the last 3 months.
Select...
I have acute anemia.
Select...
My heart's tricuspid valve can't be seen clearly for the procedure.
Select...
I cannot undergo heart imaging tests through my chest or esophagus.
Select...
I am not on IV drugs to support my heart function.
Select...
I have been taking oral steroids for 6 months or more.
Select...
I cannot take blood thinners or certain heart medications.
Select...
My heart valve issue is due to a natural cause like infection or a birth defect.
Select...
I am currently being treated for a clot or mass in my heart.
Select...
I have a narrowed tricuspid valve in my heart.
Select...
I am not pregnant or breastfeeding.
Select...
I cannot or will not receive blood transfusions.
Select...
I have had surgery on my tricuspid valve before.
Select...
I have severe kidney problems or am on dialysis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year post-adjustment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post-adjustment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Freedom from device or procedure-related mortality
Secondary study objectives
Functional: Changes in Distance Walked for Exercise Tolerance
Functional: Changes in NYHA Classification
Functional: Changes in Quality of Life Scores and Sub-Domains
+20 more
Other study objectives
Changes in Heart Failure Biomarkers
Freedom from Heart Failure Events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CI Percutaneous Ring Annuloplasty SystemExperimental Treatment1 Intervention
Patients treated with the CI Percutaneous Ring Annuloplasty System

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Tricuspid Regurgitation (TR) include medical management, surgical repair, and transcatheter interventions like the Cardiac Implants (CI) annuloplasty ring. Medical management typically involves diuretics to reduce fluid overload and medications to manage underlying conditions like heart failure. Surgical repair often includes techniques like annuloplasty, where a ring is used to reshape and stabilize the tricuspid valve annulus, thereby reducing regurgitation. The CI annuloplasty ring, specifically, is a transcatheter device that reshapes and stabilizes the tricuspid valve annulus, reducing regurgitation by ensuring better leaflet coaptation. This is crucial for TR patients as it directly addresses the structural issues causing the regurgitation, potentially improving symptoms and reducing the risk of heart failure.

Find a Location

Who is running the clinical trial?

Cardiac Implants LLCLead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled
Noa Avisar, PhDStudy DirectorCardiac Implants LLC
2 Previous Clinical Trials
260 Total Patients Enrolled
Nodar Kipshidze, MPHStudy DirectorCardiac Implants LLC
1 Previous Clinical Trials
15 Total Patients Enrolled

Media Library

CI Percutaneous Ring Annuloplasty System (Annuloplasty Ring) Clinical Trial Eligibility Overview. Trial Name: NCT04890821 — N/A
Tricuspid Regurgitation Research Study Groups: CI Percutaneous Ring Annuloplasty System
Tricuspid Regurgitation Clinical Trial 2023: CI Percutaneous Ring Annuloplasty System Highlights & Side Effects. Trial Name: NCT04890821 — N/A
CI Percutaneous Ring Annuloplasty System (Annuloplasty Ring) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04890821 — N/A
~4 spots leftby Dec 2025